|
1
|
Ramsey HE, Fischer MA, Lee T, Gorska AE,
Arrate MP, Fuller L, Boyd KL, Strickland SA, Sensintaffar J, Hogdal
LJ, et al: A novel MCL1 inhibitor combined with venetoclax rescues
venetoclax-resistant acute myelogenous leukemia. Cancer Discov.
8:1566–1581. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parkin B, Londoño-Joshi A, Kang Q, Tewari
M, Rhim AD and Malek SN: Ultrasensitive mutation detection
identifies rare residual cells causing acute myelogenous leukemia
relapse. J Clin Invest. 127:3484–3495. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Abelson S, Collord G, Ng SWK, Weissbrod O,
Mendelson Cohen N, Niemeyer E, Barda N, Zuzarte PC, Heisler L,
Sundaravadanam Y, et al: Prediction of acute myeloid leukaemia risk
in healthy individuals. Nature. 559:400–404. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: Metazoan MicroRNAs. Cell.
173:20–51. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Berindan-Neagoe I, Monroig PC, Pasculli B
and Calin GA: MicroRNAome genome: A treasure for cancer diagnosis
and therapy. CA Cancer J Clin. 64:311–336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Trino S, Lamorte D, Caivano A, Laurenzana
I, Tagliaferri D, Falco G, Del Vecchio L, Musto P and De Luca L:
MicroRNAs as new biomarkers for diagnosis and prognosis, and as
potential therapeutic targets in acute myeloid leukemia. Int J Mol
Sci. 19(pii): E4602018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wallace JA and O'Connell RM: MicroRNAs and
acute myeloid leukemia: Therapeutic implications and emerging
concepts. Blood. 130:1290–1301. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao Q, Feng J, Li W, Shen K, Chen S, Xie
Y, Zhao C and Hou Y: Expression and mechanism of plasma miR-372 in
acute myeloid leukemia patients. J Pract Med. 34:2030–2034.
2018.
|
|
9
|
Jiang X, Huang H, Li Z, He C, Li Y, Chen
P, Gurbuxani S, Arnovitz S, Hong GM, Price C, et al: miR-495 is a
tumor-suppressor microRNA down-regulated in MLL-rearranged
leukemia. Proc Natl Acad Sci USA. 109:19397–19402. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang F, Wang XS, Yang GH, Zhai PF, Xiao Z,
Xia LY, Chen LR, Wang Y, Wang XZ, Bi LX, et al: miR-29a and
miR-142-3p downregulation and diagnostic implication in human acute
myeloid leukemia. Mol Biol Rep. 39:2713–2722. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ohyashiki JH, Umezu T, Kobayashi C,
Hamamura RS, Tanaka M, Kuroda M and Ohyashiki K: Impact on cell to
plasma ratio of miR-92a in patients with acute leukemia: In vivo
assessment of cell to plasma ratio of miR-92a. BMC Res Notes.
3:3472010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yan J, Wu G, Chen J, Xiong L, Chen G and
Li P: Downregulated miR-217 expression predicts a poor outcome in
acute myeloid leukemia. Cancer Biomark. 22:73–78. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang X, Huang M, Kong L and Li Y: miR-372
suppresses tumour proliferation and invasion by targeting IGF2BP1
in renal cell carcinoma. Cell Prolif. 48:593–599. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yeh LY, Liu CJ, Wong YK, Chang C, Lin SC
and Chang KW: miR-372 inhibits p62 in head and neck squamous cell
carcinoma in vitro and in vivo. Oncotarget. 6:6062–6075. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mao Y, Li L, Liu J, Wang L and Zhou Y:
miR-495 inhibits esophageal squamous cell carcinoma progression by
targeting Akt1. Oncotarget. 7:51223–51236. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen Y, Luo D, Tian W, Li Z and Zhang X:
Demethylation of miR-495 inhibits cell proliferation, migration and
promotes apoptosis by targeting STAT-3 in breast cancer. Oncol Rep.
37:3581–3589. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu J, Jin L, Jiang L, Gao L, Zhou J, Hu Y,
Li W, Zhi Q and Zhu X: Serum miR-372 is a diagnostic and prognostic
biomarker in patients with early colorectal cancer. Anticancer
Agents Med Chem. 16:424–431. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang C, Yun Z, Zhao T, Liu X and Ma X:
miR-495 is a predictive biomarker that downregulates GFI1
expression in medulloblastoma. Cell Physiol Biochem. 36:1430–1439.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chou WC, Chou SC, Liu CY, Chen CY, Hou HA,
Kuo YY, Lee MC, Ko BS, Tang JL, Yao M, et al: TET2 mutation is an
unfavorable prognostic factor in acute myeloid leukemia patients
with intermediate-risk cytogenetics. Blood. 118:3803–3810. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Green ML, Leisenring WM, Xie H, Walter RB,
Mielcarek M, Sandmaier BM, Riddell SR and Boeckh M: CMV
reactivation after allogeneic HCT and relapse risk: Evidence for
early protection in acute myeloid leukemia. Blood. 122:1316–1324.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Björkholm M, Derolf AR, Hultcrantz M,
Kristinsson SY, Ekstrand C, Goldin LR, Andreasson B, Birgegård G,
Linder O, Malm C, et al: Treatment-related risk factors for
transformation to acute myeloid leukemia and myelodysplastic
syndromes in myeloproliferative neoplasms. J Clin Oncol.
29:2410–2415. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thol F, Damm F, Lüdeking A, Winschel C,
Wagner K, Morgan M, Yun H, Göhring G, Schlegelberger B, Hoelzer D,
et al: Incidence and prognostic influence of DNMT3A mutations in
acute myeloid leukemia. J Clin Oncol. 29:2889–2896. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gu H, Guo X, Zou L, Zhu H and Zhang J:
Upregulation of microRNA-372 associates with tumor progression and
prognosis in hepatocellular carcinoma. Mol Cell Biochem. 375:23–30.
2013.PubMed/NCBI
|
|
25
|
Michallet M, Bénet T, Sobh M, Kraghel S,
El Hamri M, Cannas G, Nicolini FE, Labussière H, Ducastelle S,
Barraco F, et al: Invasive aspergillosis: An important risk factor
on the short- and long-term survival of acute myeloid leukemia
(AML) patients. Eur J Clin Microbiol Infect Dis. 31:991–997. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Deschler B and Lübbert M: Acute myeloid
leukemia: Epidemiology and etiology. Cancer. 107:2099–2107. 2006.
View Article : Google Scholar : PubMed/NCBI
|
